EXEL – Exelixis, Inc.

Exelixis, Inc.

EXEL

$36.85

Name : Exelixis, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $10,313,614,336.00

EPSttm : 1.76

Exelixis, Inc.

$36.85

5.02%

$1.76

Float Short %

4.81

Margin Of Safety %

Put/Call OI Ratio

0.4

EPS Next Q Diff

0.08

EPS Last/This Y

EPS This/Next Y

0.54

Price

36.84

Target Price

Analyst Recom

1.96

Performance Q

6.75

Relative Volume

1.52

Beta

0.6

Ticker: EXEL

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	EXEL	34.13	0.33	0.21	26223
2025-01-24	EXEL	32.37	0.32	0.08	28094
2025-01-27	EXEL	32.73	0.34	1.49	28024
2025-01-28	EXEL	32.59	0.38	0.21	27743
2025-01-29	EXEL	32.94	0.38	0.06	27794
2025-01-30	EXEL	32.94	0.37	0.52	28368
2025-01-31	EXEL	33.12	0.37	0.06	28572
2025-02-03	EXEL	32.89	0.37	0.21	28883
2025-02-04	EXEL	33.13	0.37	0.26	28968
2025-02-05	EXEL	33.56	0.37	0.15	29165
2025-02-06	EXEL	33.66	0.37	0.20	29563
2025-02-07	EXEL	33.49	0.37	0.17	29909
2025-02-10	EXEL	33.52	0.37	0.23	30400
2025-02-11	EXEL	32.82	0.37	0.62	31587
2025-02-12	EXEL	32.82	0.38	0.31	32555
2025-02-13	EXEL	34.49	0.38	0.04	32717
2025-02-14	EXEL	35	0.37	0.08	33205
2025-02-18	EXEL	34.21	0.35	0.15	34708
2025-02-19	EXEL	35.08	0.35	0.58	34880
2025-02-20	EXEL	35.08	0.39	0.35	36813
2025-02-21	EXEL	36.83	0.40	0.46	37396
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	EXEL	34.13	53.6	-59.4	1.95
2025-01-24	EXEL	32.37	53.6	-112.0	1.95
2025-01-27	EXEL	32.72	53.6	-75.5	1.95
2025-01-28	EXEL	32.58	53.6	-84.4	1.95
2025-01-29	EXEL	32.94	54.7	-75.6	1.95
2025-01-30	EXEL	32.93	52.5	149.2	1.95
2025-01-31	EXEL	33.14	46.8	155.5	1.95
2025-02-03	EXEL	32.88	46.8	143.1	1.95
2025-02-04	EXEL	33.13	46.8	156.4	1.95
2025-02-05	EXEL	33.56	46.8	160.8	1.95
2025-02-06	EXEL	33.66	46.8	152.8	1.95
2025-02-07	EXEL	33.49	46.8	145.5	1.95
2025-02-10	EXEL	33.50	46.8	150.5	1.95
2025-02-11	EXEL	32.82	46.8	132.8	1.95
2025-02-12	EXEL	32.81	46.8	147.7	1.95
2025-02-13	EXEL	34.49	46.8	111.8	2.40
2025-02-14	EXEL	35.00	46.8	80.7	2.31
2025-02-18	EXEL	34.23	146.0	49.9	2.31
2025-02-19	EXEL	35.07	146.0	89.6	2.31
2025-02-20	EXEL	35.08	146.0	68.6	2.31
2025-02-21	EXEL	36.84	146.0	110.1	2.31
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	EXEL	-8.63	2.60	3.76
2025-01-24	EXEL	-8.63	2.60	3.76
2025-01-27	EXEL	-8.63	2.72	3.76
2025-01-28	EXEL	-8.63	2.72	5.20
2025-01-29	EXEL	-8.63	2.72	5.20
2025-01-30	EXEL	-8.63	2.72	5.20
2025-01-31	EXEL	-8.63	2.72	5.20
2025-02-03	EXEL	-8.63	2.18	5.20
2025-02-04	EXEL	-8.63	2.18	5.20
2025-02-05	EXEL	-8.63	2.18	5.20
2025-02-06	EXEL	-8.63	2.18	5.20
2025-02-07	EXEL	-8.63	2.18	5.20
2025-02-10	EXEL	-5.14	2.70	5.21
2025-02-11	EXEL	-4.84	2.70	5.21
2025-02-12	EXEL	-4.84	2.70	4.72
2025-02-13	EXEL	-4.47	2.70	4.72
2025-02-14	EXEL	-4.78	2.70	4.81
2025-02-18	EXEL	-4.43	2.27	4.81
2025-02-19	EXEL	-4.40	2.27	4.81
2025-02-20	EXEL	-5.37	2.27	4.81
2025-02-21	EXEL	-5.37	2.27	4.81
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.48

Avg. EPS Est. Current Quarter

0.42

Avg. EPS Est. Next Quarter

0.56

Insider Transactions

-5.37

Institutional Transactions

2.27

Beta

0.6

Average Sales Estimate Current Quarter

495

Average Sales Estimate Next Quarter

549

Fair Value

48.1

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-45.4

Target Price

P/E

20.79

Forward P/E

15.67

PEG

1.01

P/S

4.76

P/B

4.63

P/Free Cash Flow

15.36

EPS

1.77

Average EPS Est. Cur. Y

2.31

EPS Next Y. (Est.)

2.85

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.04

Relative Volume

1.52

Return on Equity vs Sector %

Return on Equity vs Industry %

19.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.22

EBIT Estimation

110.1

Exelixis, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1147

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

stock quote shares EXEL – Exelixis, Inc. Stock Price stock today

news today EXEL – Exelixis, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EXEL – Exelixis, Inc. yahoo finance google finance

stock history EXEL – Exelixis, Inc. invest stock market

stock prices EXEL premarket after hours

ticker EXEL fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

EXEL – Exelixis, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: EXEL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y